My Pregnancy Care

  • Research type

    Research Study

  • Full title

    Combined self-monitoring for hypertensive pregnancy: A feasibility trial

  • IRAS ID

    333984

  • Contact name

    Katherine Tucker

  • Contact email

    katherine.tucker@phc.ox.ac.uk

  • Duration of Study in the UK

    1 years, 7 months, 1 days

  • Research summary

    Currently, 1 in 20 pregnancies occurs in a woman who has longstanding hypertension, for which they are usually taking medication to control. If a pregnant woman has longstanding high blood pressure, there is a 1 in 4 chance that she will develop pre-eclampsia. Pre-eclampsia is a serious condition which is diagnosed by a rising blood pressure and protein in the urine. Currently, pregnant women with hypertension have frequent clinic appointments for monitoring, and to make any changes needed to their blood pressure medications. Early detection of rising blood pressure and / or protein in the urine can reduce the risk of future complications for mother and baby.
    There have been recent trials investigating the use of self-monitoring of blood pressure in pregnancy, where women check their blood pressure readings daily at home, and use these to guide their management. These have been shown self-monitoring to be safe, cost-effective and well-received by participants, but more research is needed into how to use it to improve outcomes. This study will ask participants to self-monitor their blood pressure daily, test their urine weekly for protein, and submit these readings into a mobile phone app. Via the app, their healthcare team will be able to recommend if an increase in their medication is needed based on their readings, or if a clinical review is required, with the aim that earlier detection of changes will improve outcomes. This study is to assess the feasibility of this process, before the development of larger scale clinical trials to investigate the impact on outcomes.

  • REC name

    East of England - Cambridge South Research Ethics Committee

  • REC reference

    24/EE/0045

  • Date of REC Opinion

    19 Mar 2024

  • REC opinion

    Further Information Favourable Opinion